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Background: Primary care plays a key role in the prevention and management of cardiovascular disease (CVD). We
examined primary care practice adherence to recommended care guidelines associated with the prevention and
management of CVD for high risk patients.
Methods: We conducted a secondary analysis of cross-sectional baseline data collected from 84 primary care
practices participating in a large quality improvement initiative in Eastern Ontario from 2008 to 2010. We collected
medical chart data from 4,931 patients who either had, or were at high risk of developing CVD to study adherence
rates to recommended guidelines for CVD care and to examine the proportion of patients at target for clinical
markers such as blood pressure, lipid levels and hemoglobin A1c.
Results: Adherence to preventive care recommendations was poor. Less than 10% of high risk patients received a
waistline measurement, half of the smokers received cessation advice, and 7.7% were referred to a smoking
cessation program. Gaps in care exist for diabetes and kidney disease as 54.9% of patients with diabetes received
recommended hemoglobin-A1c screenings, and only 55.8% received an albumin excretion test. Adherence rates to
recommended guidelines for coronary artery disease, hypertension, and dyslipidemia were high (>75%); however
<50% of patients were at target for blood pressure or LDL-cholesterol levels (37.1% and 49.7% respectively), and
only 59.3% of patients with diabetes were at target for hemoglobin-A1c.
Conclusions: There remain significant opportunities for primary care providers to engage high risk patients in
prevention activities such as weight management and smoking cessation. Despite high adherence rates for
hypertension, dyslipidemia, and coronary artery disease, a significant proportion of patients failed to meet treatment
targets, highlighting the complexity of caring for people with multiple chronic conditions.
Trial Registration: NCT00574808
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Cardiovascular disease (CVD) is the leading cause of
death and disability in Canada [1,2], with 447,000 hospi-
talizations and 3.9 million patient days in the hospital
each year, contributing to an overall yearly cost of $18.5
billion [3-5]. With an increasingly aging Canadian* Correspondence: cliddy@bruyere.org
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reproduction in any medium, provided the orpopulation, the number of deaths and overall burden of
CVD is predicted to double by the year 2018 [6].
Primary care providers are well placed to play a central
role in preventing and managing CVD and other chronic
diseases, as 95% of Canadian adults with chronic condi-
tions in Canada report having a regular family physician
[7]. The frequent visits these patients make to their pri-
mary care provider offer a unique opportunity to moni-
tor patients’ cardiovascular health, encourage a healthy
lifestyle, and ensure preventive care [8,9].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in 84 primary care practices in Eastern Ontario, Canada,
we studied practice-level adherence to recommended
guidelines, in nine areas of care including coronary ar-
tery disease, peripheral vascular disease, stroke/transient
ischemic attack, chronic kidney disease, diabetes, dyslipi-
demia, hypertension, smoking cessation care, and weight
management. To the best of our knowledge, this is the
most comprehensive evaluation of CVD care to ever be
conducted in primary care practices in Canada.Methods
Study design
This is a secondary analysis of pooled cross-sectional
baseline data collected through a larger quality improve-
ment initiative known as the Improved Delivery of Car-
diovascular Care (IDOCC) through Outreach Facilitation
project (www.idocc.ca) [10]. IDOCC received ethical ap-
proval from the Ottawa Hospital Research Ethics Board.
The objective of IDOCC was to assist primary care
providers in improving their delivery of evidence-based
care for the secondary prevention of heart disease, stroke,
peripheral vascular disease, renal disease, and diabetes.
IDOCC used trained facilitators who work with health
care providers for 24 months within their practices to
help them incorporate elements of the Chronic Care
Model into daily care routines [11]. The IDOCC inter-
vention was evaluated using a cluster randomized con-
trolled trial. The intervention was delivered to groups of
practices in three distinct steps (26–30 practices per
step), with each consecutive step beginning the program
approximately one year apart (i.e., Step I: 2008, Step II:
2009, Step III: 2010). Intervention delivery was rando-
mized at the regional level, with each step containing
three regions, for a total of nine regions.
The first stage of the IDOCC intervention consisted of
a chart audit intended to understand the strengths and
gaps in care delivery within each practice in order to in-
form the components of the facilitation intervention.
These baseline data are used in this secondary analysis
to report on the quality of CVD care in primary care
practices in Eastern Ontario.Study setting
The geographic setting for this study was the Champlain
Local Health Integration Network (LHIN), which is one
of 14 regional health districts in Ontario and encom-
passes Ottawa and its surrounding communities. The
Champlain LHIN is a culturally diverse region with a
population of 1.2 million people who have chronic dis-
ease burdens and patient health outcomes which are
comparable to Ontario and the rest of Canada [12].Sample
All practices providing general primary care services and
planning to remain in operation for the subsequent two
years were eligible to participate, regardless of the practice’s
team structure, rurality, group size, or provider remuner-
ation structure (fee-for-service, capitation, or salary-based).
Walk-in only clinics were excluded.
We approached all 434 eligible practices in the Cham-
plain LHIN with the intent of recruiting a minimum of
27 practices per step, as per the sample size requirements
of the IDOCC study [10]. In each step, recruitment con-
tinued until at least 30 practices were enrolled. In total,
93 practices were recruited: 30, 33, and 30 in Steps I, II,
and III, respectively. All participating practices com-
pleted a practice characteristic survey highlighting details
about their practice organizational structure, including
primary care model type and number of patients. Physi-
cians also provided consent to allow the study investiga-
tors to access information about their practices stored in
health administrative databases stored at the Institute for
Clinical Evaluative Sciences (ICES). Further details about
the practice recruitment process are presented elsewhere
[10].
Medical chart audits for patients with or at high risk
of CVD were used to assess each practice’s adherence to
evidence-based guidelines for CVD care. Eligible patients
for the chart audit were those over 40 years of age who
met at least one of the following criteria: 1. Cardiovascu-
lar disease including coronary artery disease, cerebrovas-
cular disease (stroke and/or transient ischemic attack),
or peripheral vascular disease; 2. Diabetes mellitus; 3.
Chronic kidney disease; 4. at high risk for cardiovascular
disease based on the presence of at least three of the fol-
lowing cardiovascular risk factors as defined by the Fra-
mingham Risk Score: age (male ≥ 45, female ≥ 55),
smoker, hypertension, and dyslipidemia [13].
Data collection
Six chart abstractors audited medical chart data across
the following four areas: 1. Cardiovascular disease/risk
factor screening, 2. Drug prescriptions relating to CVD,
3. Referral to external programs (e.g., referral to smoking
cessation programs) and 4. Clinical measures (e.g., blood
pressure, lipid profiles, etc.). We designed a chart ab-
straction manual that included information about mak-
ing initial contact with the practice, instructions for
ensuring patient confidentiality, information on asses-
sing patient eligibility (including a list of synonyms for
each condition), data entry instructions, and a copy of
the chart abstraction form containing the data elements
to be collected from each chart. A more detailed de-
scription of the application of chart audits and the meth-
odology used can be found in separate publications
[10,14]. Patient charts were randomly selected using
Table 1 Process of care manoeuvres
Area of care Process of care manoeuvres*




receptor blocker, beta blocker
ASA
















Diabetes Two hemoglobin A1c tests
Glycemic control medication





Chronic Kidney Disease ACR




Hypertension Two blood pressure readings
Anti-hypertensive medication




Dietician or weight loss program
ACE – Angiotensin converting enzyme, ACR - Albumin-to-creatinine ratio, ASA
– Acetylsalicylic acid.
CT – Computed Tomography, eGFR - Estimated glomerular filtration rate, EKG
– Electrocardiogram.
* assessed whether recommended care manoeuvres were performed,
recommended, or discussed during the one year preceding the abstraction
date.
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measure method’ for paper and mixed charting systems
(i.e., paper and electronic records) and a random num-
ber generator for practices using only electronic records
[14]. We aimed to abstract a minimum of 45 charts from
each practice. Chart abstractors were blinded to primary
and secondary outcomes of the IDOCC study.
To ensure the quality of the abstracted data across
chart abstractors, a four-part quality implementation
and monitoring process was established. The process
involved: 1. Standardized protocol implementation, 2.
Extensive data abstraction training, 3. Continuous re-
abstraction and validation among abstractors to monitor
the inter-rater reliability, and 4. Constant chart ab-
stractor feedback and re-training [15]. The baseline
inter-rater reliability kappa value was 0.91 and the over-
all percent agreement was 94.3%.
In addition, we assessed potential selection biases by
linking to administrative databases stored at ICES in
order to compare practice, physician and patient-level
profiles between participating physicians and physicians
from the Champlain region who opted not to participate
in IDOCC. We also collected data for all physicians
within the province of Ontario in order to gain insight
into the generalizability of our findings.
Outcome measures
The selection of care indicators was based on recom-
mendations from a locally developed integrated CVD
prevention and management guideline tailored to pri-
mary care: The Champlain Primary Care Cardiovascular
Disease Prevention and Management Guideline [16].
This guideline was derived by an expert panel of family
physicians and specialists (e.g., cardiologists, endocrinol-
ogists, etc.) who critically reviewed and harmonized
current national and international guidelines for CVD
and its risk factors using the AGREE methodology [17].
The guideline is updated on an annual basis and is avail-
able in English and French. The guideline can be viewed
at www.idocc.ca.
Processes of care: We assessed whether recommended
care manoeuvres were performed, recommended, or dis-
cussed during the one year preceding the abstraction
date. For example, for patients with diabetes, we exam-
ined whether two hemoglobin A1c (HbA1c) tests were
recommended, discussed or performed in the chart audit
year. A list of all of the process of care manoeuvres
examined is presented in Table 1. Patients with multiple
conditions were assessed separately for manoeuvres
associated with each individual condition.
Clinical test results were also assessed to determine the
proportion of individuals within the recommended target
range for each of the following clinical markers: blood
pressure (<130/80 mmHg for patients with diabetes or




Solo physician 29 (34.5%)





Salary- Community Health Centres 12 (14.6%)
Urban practices 69 (82.1%)
EMR – Electronic medical record, FFS – Fee-for-service.
* Two Long-term care centres were not included in this breakdown.
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lipoprotein (LDL) (<2.0 mmol/L), glycemic level
(HbA1c < 7.0%, Fasting Blood Glucose (FBG) < 7 mmol
and>4 mmol/L) and proteinuria (Albumin-to-creatinine
(ACR) <40).
Data analysis
Practice and patient characteristics are described using
frequencies and proportions or means and standard
deviations. Process of care indicators and clinical test
results are described as proportions with 95% confidence
intervals, adjusted for clustering of patients within prac-
tices [18]. All analyses were conducted using a commer-
cially available software package (SAS, Version 9.2, SAS
Institute Inc) [19].
Results
194 physicians in 93 practices consented to participate in
IDOCC. Compared to non-participants (i.e., those physi-
cians in the Champlain region who declined to partici-
pate in IDOCC) and all physicians in Ontario, IDOCC
physicians were more likely to be female (IDOCC: 54.3%,Table 3 Patient Profile (n = 4,931)
Characteristics
Age (mean, SD) 66.4 (11.8)
Male (n,%) 2386 (48.4%)
Coronary Artery Disease (n,%) 1510 (30.6%)
Peripheral Vascular Disease (n,%) 318 (6.5%)
Stroke/Transient Ischemic Attack (n,%) 636 (12.9%)
Diabetes (n,%) 2308 (46.8%)
Chronic Kidney Disease (n,%) 916 (18.6%)
Hypertension (n,%) 3793 (76.9%)
Dyslipidemia (n,%) 4111 (83.4%)
Smoke (n,%) 1049 (21.2%)
# of Cardiovascular-related comorbidities (mean, SD) 2.8 (1.1)IDOCC non-participants: 43.0%, Ontario: 36.5%), trained
in Canada (IDOCC: 90%, IDOCC non-participants:
82.1%, Ontario: 76.7%), and to practice in a clinic that
employed a capitated remuneration model (IDOCC:
29.5%, IDOCC non-participants: 12.6%, Ontario: 16.5%).
Of the 93 practices that agreed to participate in
IDOCC, nine practices dropped out prior to baseline
data collection for various reasons including not having
the office space to accommodate a chart abstractor,
while several small practices did not have the 45 eligible
patient charts necessary for entry into the study. The 84
participating practices varied in their team structure,
physician remuneration approach, and rurality (Table 2).
We collected medical chart data from an average of 59
patients per practice, for a total of 4,931 patients. Demo-
graphics and disease conditions for this group of
patients are summarized in Table 3.
Adherence to processes of care delivery
Practices had a high level of adherence to recommended
guidelines associated with coronary artery disease,
hypertension and dyslipidemia, with adherence rates of
75% or higher for each manoeuvre associated with these
conditions (Table 4).
Gaps in care delivery were seen for diabetes manage-
ment as only about half (54.9%, 95% CI [50.1-59.6%]) of
the patient group had two HbA1c measures done in one
year. Similarly, measurement of albumin excretion
(ACR) was also only done for approximately half (55.8%,
95% CI [50.6 - 61.0%]) of the patients with diabetes.
ACR screening was also poor amongst patients with
known chronic kidney disease (51.6%, CI [46.3-57.0%]).
There was a low level of adherence to preventive care
guidelines. Waist circumference measurements were
done in only 9.9% (95% CI [6.7 – 13.0%]) of these high
risk patients, while few were referred for dietary advice
(18.2%, 95% CI [14.3-22.2%]). The highest level of adher-
ence for waist circumference measurement and referral
for dietary advice was seen for patients with diabetes
(14.3% [9.4-19.2%] and 25% [20.1-29.9%] respectively),
however, levels were still quite low. Similarly, less than
half of the smokers had documented evidence of receiv-
ing smoking cessation advice (52.8%, 95% CI [46.9-
58.8%]), 7.7% (95% CI [5.1-10.6%]) were referred to a
smoking cessation program, and less than a quarter
(23.1%, 95% CI [19.2-27.1%]) were recommended or pre-
scribed any pharmacotherapy to assist with quitting.
Patient clinical measures
Less than half of all high risk patients who had a lipid
profile or blood pressure measure (37.1%, 95% CI [34.3-
39.8%]; and 49.7%, 95% CI [47.1-52.3%] respectively)
were within the recommended target range (Table 5).
Patients that did not have established CVD, diabetes, or
Table 4 Adherence to guidelines across 84 primary car
practices*
Process of care manoeuvre Percentage of patients
receiving care [95% CI]
All (n = 4931)
2 Blood pressure measures 74.8% [71.3-78.3%]
Lipid profile 77.7% [74.9-80.4%]
Waist circumference measure 9.9% [6.7-13.0%]
Dietician/weight loss program referral 18.2% [14.3-22.2%]
Smoking status recorded 95.4% [93.9-97.0%]
Coronary Artery Disease (n = 1510)
Fasting blood glucose 80.0% [77.2-82.8%]
Medication (ACE, Angiotensin
receptor blocker, beta blocker)
88.5% [86.5-90.4%]
ASA 76.0% [73.2-78.9%]
Peripheral Vascular Disease (n = 318)
Fasting blood glucose 78.9% [74.6-83.2%]
ACE inhibitor and/or Angiotensin
receptor blocker
66.9% [61.4-72.5%]
Lipid lowering medication 83.3% [77.8-88.8%]
ASA 75.8% [70.3-81.2%]
Stroke (n = 636)
Fasting blood glucose 76.9% [72.8-81.0%]
ASA 78.9% [74.7-83.2%]
If stroke within past year (n = 71)
Echo cardiogram 47.9% [38.6-65.6%]
Carotid doppler 59.6% [43.7-74.7%]
CT head scan 66.2% [52.6-79.8%]
EKG 52.1% [38.6-65.6%]
Diabetes (n = 2308)
Two hemoglobin A1c tests 54.9% [50.1-59.6%]
Glycemic control medication 80.5% [78.0-83.0%]
ACR 55.8% [50.6-61.0%]
eGFR 83.8% [80.8-86.8%]
Chronic Kidney Disease (n = 916)
ACR 51.6% [46.3-57.0%]
Dyslipidemia (n = 4111)
Lipid profile 82.8% [80.9-84.7%]
Lipid lowering medication 91.5% [90.1-92.8%]
Hypertension (n = 3793)
Two blood pressure readings 79.4% [76.0-82.8%]
Anti-Hypertensive medication 94.2% [93.1-95.3%]
Smoking (n = 1049)
Smoking cessation counselling 52.8% [46.9-58.8%]
Smoking cessation program 7.7% [5.1-10.6%]
Smoking cessation drug 23.1% [19.2-27.1%]
ACE Angiotensin converting enzyme, ACR Albumin to creatinine ratio, ASA
Acetylsalicylic acid, CT Computed Tomography, eGFR estimated glomerular
filtration rate, EKG Electrocardiogram.
* assessed whether recommended manoeuvres were performed,
recommended, or discussed during the one year preceding the abstraction
date.
Table 5 Percentage of patients at clinical targets
Clinical Outcome Percentage of Patients at
Target* Levels [95% CI]
All
Blood pressure (n = 4581) 49.7% [47.1-52.3%]
LDL (n = 3661) 37.1% [34.3-39.8%]
Fasting blood glucose (n = 3892) 70.5% [68.5-72.5%]
ACR (n = 1534) 95.8% [94.8-96.7%]
Coronary Artery Disease
Blood pressure (n = 1393) 60.2% [56.3-64.1%]
LDL (n = 1094) 51.7% [47.5-56.0%]
Fasting blood glucose (n = 1190) 77.1% [74.6-79.5%]
Peripheral Vascular Disease
Blood pressure (n = 302) 54.0% [47.6-60.3%]
LDL (n = 219) 52.5% [44.8-60.3%]
Fasting blood glucose (n = 247) 73.7% [69.2-78.2%]
Stroke
Blood pressure (n = 588) 59.9% [55.0-64.7%]
LDL (n = 403) 44.4% [39.4-49.4%]
Fasting blood glucose (n = 475) 79.4% [76.0-82.8%]
Diabetes
Hemoglobin A1c (n = 1924) 59.3% [56.6-62.0%]
Blood pressure (n = 2137) 34.1% [31.1-37.2%]
LDL (n = 1793) 47.1% [43.4-50.9%]
ACR (n = 1155) 95.3% [94.2-96.4%]
Chronic Kidney Disease
ACR (n = 435) 89.0% [86.4-91.5%]
Blood pressure (n = 867) 40.6% [35.8-45.4%]
LDL (n = 660) 48.8% [44.2-53.4%]
Dyslipidemia
LDL (n = 3262) 39.7% [36.9-42.5%]
Hypertension
Blood pressure (n = 3587) 46.9% [44.1-49.7%]
Risk Factor Only†
Blood pressure (n = 1042) 62.8% [58.6-66.9%]
LDL (n = 835) 13.8% [11.3-16.3%]
Fasting blood glucose (n = 839) 97.3% [96.1-98.4%]
ACR – Albumin to creatinine ratio, LDL – Low density lipoprotein.
* Target levels:
Blood pressure: <130/80 for those patients that have diabetes and/or chronic
kidney disease and 140/90 for all other patients.
LDL < 2.0 mmol/L, ACR < 40, Fasting Blood Glucose (<7 mmol/L, > 4 mmol/L),
HbA1c < 7.0%.
† Patients that did not have established cardiovascular disease, diabetes or
chronic kidney disease, but were at high risk for cardiovascular disease based
on the presence of at least three of the following cardiovascular risk factors:
age (males ≥ 45, females ≥ 55), smoker, hypertension, and dyslipidemia.
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based on the presence at least three risk factors, had the
poorest control of LDL levels, while the diabetes patient
sub-group had the poorest control of their blood pres-
sure levels. Furthermore, only 59.3% (95% CI [56.6-
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for HbA1c levels (<7.0%).
Discussion
We found significant gaps in recommended care for this
high risk CVD patient group, particularly for prevention
activities such as smoking cessation and weight manage-
ment. A reduction in the smoking rate of high risk CVD
patients could significantly impact mortality [20-22].
Despite the existence of community help programs and
public health campaigns, we found low rates for counsel-
ing patients to quit smoking, smoking cessation medica-
tion prescribing, and referrals to community programs,
findings that are consistent with studies conducted
across Canada, Europe and the United States [23-27].
This is a missed opportunity for prevention as primary
care physicians are seen as a credible source of informa-
tion, and a number of studies have shown that counsel-
ling in combination with a nicotine replacement therapy
can double ones chances of successfully quitting [28].
Lack of time, competing demands, lack of reimburse-
ment, and perceived patient resistance are barriers to
care [24]. Improvements in organizing care at the level
of the practice may reduce these barriers [24], along with
patient self-management approaches such as motiv-
ational counselling [29], as well as greater linkages be-
tween the primary care practice and the community.
Our findings also highlight the significant ongoing gap
in diabetes management within primary care practices in
Eastern Ontario. Optimizing care and achieving clinical
targets could reduce mortality as people with diabetes
are at high risk of suffering a cardiovascular event
[30-33]. These findings are consistent with other inter-
national findings, as a number of studies have demon-
strated the challenges associated with treating patients
with diabetes to target levels [34-36].
Furthermore, the results of this study are consistent
with other findings in Canada and Ontario which have
demonstrated high levels of adherence to guidelines
associated with hypertension [37-39]. The adherence
rates seen in this and other Canadian studies have been
higher than those in the United States and other devel-
oped nations [40,41]. This marked improvement in
hypertension management is likely due in part to local
community programs, greater awareness and the estab-
lishment of the Canadian Hypertension Education Pro-
gram (CHEP), an initiative developed in the late nineties
to support primary care providers and patients by pro-
viding them with guidelines and recommendations for
managing and preventing hypertension [42].
We found a spectrum in uptake patterns for new evi-
dence in primary care. For example, although the benefits
of measuring eGFR levels in diagnosing and managing
chronic kidney disease were not published until 2004 [43],uptake of this guideline in primary care has been rapid at
least in part to the automatic reporting of eGFR by labora-
tories when serum creatinine is requested. This is appar-
ent as 84% of patients with diabetes had undergone eGFR
testing in this study. Similar uptake patterns have been
seen internationally as well [44,45]. In contrast, despite
evidence that waistline is a strong predictor of cardiovas-
cular related morbidity and mortality and has been recom-
mended since 1998 [46], only one in ten patients had a
measure done [47,48]. Low levels of uptake have also been
documented in other countries [49,50]. One study
reported that family physicians cited lack of time, extra
workload, opportunity costs, and concerns about the ac-
ceptability of this manoeuvre as barriers to uptake [50].
Despite high adherence by providers to recommended
guidelines for patients with hypertension, dyslipidemia
and coronary artery disease, a high proportion of
patients still did not meet clinical target levels, an obser-
vation that is likely due to several factors. For example,
low patient compliance to medications could have
impacted poor control rates, however, we are unable to
confirm this from chart audit data alone. Also, changing
guideline targets such as the recent changes made to the
Canadian Lipid Guidelines in 2006, which decreased the
target LDL level from 2.5 mmol/L to the more stringent
2.0 mmol/L may have also impacted the rates [51]. Fur-
thermore, some experts have suggested that the choice
of medication and a lack of dose titration are two poten-
tial reasons for poor LDL control rates [52], while a re-
cent study suggested that 38% of high risk patients
would be unable to reach an LDL target of <2.0 mmol/L
even when using a maximum dose statin monotherapy
[53]. As well, this difficulty in management could poten-
tially be due in part to clinical inertia - resistance of a
health care provider to intensify therapy when indicated
– as there could be a need to change drug therapies,
doses or initiate counselling to change lifestyle habits (e.
g., diet, exercise, etc.). Alternately, the poor control rates
may simply highlight the complexities of controlling
LDL and blood pressure levels in high risk multimorbid
patients.
Translating research evidence into practice is challen-
ging as the research which underpins clinical guidelines
is often obtained from studies that exclude patients with
multimorbidities like the ones examined in this study
[54-56]. As such, a cogent case can be made that guide-
lines may not easily apply to patients with multimorbid-
ities. For example, if a multimorbid patient is newly
diagnosed with hypertension and is already taking mul-
tiple medications, it may be less appropriate for a pri-
mary care physician to prescribe an additional drug.
This is a concern when interpreting papers that look at
guideline adherence, as most simply report on whether a
treatment was delivered or not, even when it may be
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capture whether appropriate care was delivered, we
recorded physicians as adhering to a guideline if the spe-
cific care manoeuvre was performed, recommended or
considered, regardless of whether the patient followed
the recommendation such as compliance to prescrip-
tions. This could also explain some of the gaps between
processes and clinical outcomes in our results.
Study limitations
Although the participants in this study represent diverse
family practices, they all voluntarily participated in
IDOCC resulting in a potential selection bias. We found
differences in physician sex, training background and re-
muneration model between IDOCC participants and
both non-participants and provincial averages. This bias
may impact the generalizability of our findings, as prac-
tices that tend to take part in quality improvement initia-
tives such as IDOCC, are likely highly motivated and are
higher performing than provincial averages. As such, we
anticipate that the gaps in care observed in this study are
likely greater amongst the entire practice population in
Eastern Ontario. Also, we were only able to present clin-
ical test results for those who had screenings during the
chart audit year, and thus, we are unable to comment on
control rates for those who did not have any tests done.
We presented summary indicators of the quality of CVD
care using baseline data from three groups of primary
care practices enrolled over three distinct steps. Al-
though these data were collected over a three year period
(2007–2009), we did not explore the presence of any
trends in quality over time, because trends would have
likely been confounded with observed differences among
the groups of practices allocated to the different steps in
the stepped wedge design [57]. Lastly, this study had a
measurement bias. As with all studies relying on chart
audits, we could only assess guideline adherence through
implication - activities performed but not charted would
not have been captured by our methodology. This is less
of a problem when adherence is measured by the per-
formance and interpretation of a pathology test, than
when dependent on documentation of clinical activities
(such as providing advice to smokers to quit). Another
limitation of using medical chart data was that we were
unable to determine whether patients actually complied
with medical drug prescriptions that were given to them
by their provider, a factor that may have played a role in
patients being unable to reach clinical targets. Notwith-
standing the above limitations, chart audits are a rich
source of information and remain the standard for cap-
turing process of care data, as alternative methods of data
collection at the practice are expensive and not feasible
for large trials such as this.Conclusions
There remain significant opportunities for primary care
providers to engage high risk CVD patients in preven-
tion activities such as weight management and smoking
cessation. In addition, despite high adherence rates for
hypertension, dyslipidemia, and coronary artery disease,
a significant proportion of patients failed to meet treat-
ment targets highlighting the complexity of caring for
people with multiple chronic conditions.
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